Jane Street’s Mineralys Therapeutics MLYS Stock Holding History

Jane Street’s Portfolio MLYS Stock Details MLYS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.93M	Sell	71,300 -46,100	-39%	-$1.35M	﹤0.01%	5165
2025 Q4	$4.26M	Buy	+117,400	New	+$4.71M	﹤0.01%	3481

Other funds holding MLYS

Catalys Pacific Tokyo, Japan $231M AUM 83.19% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Jane Street's MLYS Position: Q4 2025 in Review

Jane Street sold out of Mineralys Therapeutics (MLYS) in Q4 2025, closing a stake of 37,145 shares — an estimated $1.49M sold.

Jane Street first reported a position in MLYS in Q3 2023 and held it in 5 quarters. The position peaked at $1.41M in Q3 2025. 223 funds tracked by Wall St. Rank hold MLYS as of Q4 2025.

Jane Street reported no remaining Mineralys Therapeutics position as of Q4 2025 after selling out during the quarter.
Jane Street sold 37,145 Mineralys Therapeutics shares in Q4 2025, an estimated $1.49M.
Jane Street first reported a position in Mineralys Therapeutics in Q3 2023 and held it in 5 quarters.
Jane Street's Mineralys Therapeutics position peaked at $1.41M in Q3 2025.
223 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q4 2025.

Based on Jane Street's 13F filing for Q4 2025, filed 12 Feb 2026.